Intravenous Immunoglobulin for the Treatment of Quetiapin-Induced Bullous Pemphigoid in an HIV-Infected Patient by Cabete, J et al.
Intravenous	   immunoglobulin	   for	   the	   treatment	   of	  




Cabete,	  J.;	  Santos,	  G.;	  Rocha	  Páris,	  F.;	  Serrão,	  V.;	  Fidalgo,	  A.	  
Dermatology	  Department,	  Hospital	  de	  Santo	  António	  dos	  Capuchos	  –	  C.H.L.C.,	  Lisbon,	  Portugal	  
Case	  Presenta4on	  
  48-­‐year-­‐old	  woman	  
  HIV	  infecLon	  (CD4	  319/μL,	  viral	  load	  
<50	  c/mL),	  demenLa,	  dyslipidemia	  
  Polymedicated	  (HAART,	  neurolepLcs,	  
staLn)	  
  Bullous	  pemphigoid	  
  Light	  microscopy,	  DIF	  
  Persistent	  eosinophilia	  
  	  PCR	  





  Temporary	  disease	  control	  
  Well	  tolerated,	  no	  severe	  side-­‐eﬀects	  
	   	   	  but:	  
➡  Refractory	  disease	  with	  corLcosteroid	  tapering	  
➡  Persistently	  elevated	  eosinophilia,	  and	  rising...	  
No	  response	  
No	  response	  +	  bicytopenia	  
Prednisolone	  1	  mg/Kg/day	  monotherapy	  
+	  Azathioprine	  100	  mg/day	  




Reviewing	  drug	  history:	  
  Que4apine:	   the	   last	   introduced	   drug;	   1200	   mg/day	   (above	   the	   maximum	  
recommended	  daily	  dose)	  
  QueLapine	  was	  disconLnued 	  	  
  Complete	  clinical	  resoluLon	  	  
  ResoluLon	  of	  eosinophilia	  
  Inadvertent	  rechallenge	  with	  olanzapine	  
  New	  ﬂare	  and	  eosinophilia	  	  
  Complete	  sustained	  response	  with	  queLapine/related	  drug	  withdrawal	  
  No	  need	  for	  immunosuppressors	  or	  immunomodulators	  

Discussion	  
1.  Bullous	  pemphigoid	  in	  HIV	  paLent	  
•  HIV	  and	  autoimmunity:	  a	  disease	  conLnuum?	  
•  Autoimmune	  diseases	  are	  common,	  but	  bullous	  pemphigoid	  is	  rare	  (4	  cases)	  
2.  QueLapine-­‐induced	  bullous	  pemphigoid	  
•  NeurolepLcs	  are	  associated	  with	  bullous	  pemphigoid	  
•  QueLapine:	  1	  previous	  report	  
3.  IVIG	  in	  HIV	  paLent	  
•  An	  alternaLve	  to	  immunosuppression	  
•  Widely	  used	  in	  other	  diseases	  in	  immunosuppressed	  paLents	  
  This	  rare	  case	  of	  drug-­‐induced	  bullous	  pemphigoid	  in	  an	  HIV	  paLent	  
suggests	  queLapine	  as	  a	  drug	  trigger	  for	  this	  condiLon	  
  IGIV	   appears	   to	   be	   a	   safe	   and	   eﬀecLve	   alternaLve	   to	  
immunosuppressors	  in	  immunodeﬁcient	  paLents	  with	  severe	  bullous	  
pemphigoid	  
  Safety,	   eﬃcacy,	   and	   minimum	   eﬀecLve	   dose	   studies	   in	   this	  
subpopulaLon	  are	  warranted	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